Repair and pain · part of Injury, healing and recovery and Bone and joints
Will it help my knees?
One of the two things people most often report trying peptides for, and one of the thinnest human evidence bases on this site.
1,127
people in trials
6
studies in people
2
compounds, animal or lab only
11
compounds people report on
1
trials found nothing
Measured in people
A trial that gave people the compound comes first. A study that only watched people, who happened to have more or less of something related, comes after. Both are studies in people and both are here. Only the first kind tested the thing you are asking about, and the watch-only ones are labelled. Within that, the most people come first. That is a fact about the studies, not a judgement about the compound. Counts are never added up across compounds, because the same person can be in more than one trial.
Peptides and blends
1 compound · 538 people given one of themWhat this archive is for. Trials of the compound come first, ranked by how many people were actually given it. Studies that only observed people are below them and labelled.
- 01MelittinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 5 completed trials, 658 people given it.4 reported538 people given it1 trial
This tested whole bee venom, not melittin. Five hundred and thirty eight people with knee arthritis got weekly skin injections of venom, or of a control substance, for twelve weeks. Pain and physical function improved more on the venom. The gains were modest in size. Reactions where the needle went in were uncommon. Melittin is one ingredient of bee venom, and nothing here tells you what melittin alone would do. The paper does not say who paid.
The numbers Whole purified venom, not melittin. 538 patients with knee osteoarthritis randomised 1:2 to histamine control or 100 mcg venom in 15 dermal injections at acupuncture points weekly for 12 weeks. WOMAC pain improved 1.1 points more than control (95% CI 0.3 to 2.0, p = 0.001) and physical function 3.1 points (p = 0.0046). Injection site reactions under 5 percent. Described as a phase 3; funding not stated in the abstract.
Journal of Alternative and Complementary Medicine, 2019· 538 people
What people using it report
- Bee venom therapy, with live stings or injected venom, has a long tradition among ordinary people for arthritis, multiple sclerosis and long term pain. The 2005 MS study was run because patients were already doing it. The Parkinson study used a standard allergy shot dosing plan for the same reason.
Supplements
1 compound · 95 people given one of themVitamins, minerals, amino acids and botanicals sold over the counter, held to the same standard.
- 01CurcuminSupplementModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 195 people given it.5 reported95 people given it2 trials
A high-absorption curcumin form eased knee pain in a short study. 50 adults with knee arthritis took 180 mg a day, or a dummy pill, for 8 weeks. Pain scores were lower on the curcumin form, except in people who started with almost no pain. They also needed less of the pain drug celecoxib. Eight weeks is short, and this is one form.
The numbers 50 adults with Kellgren-Lawrence grade II or III knee osteoarthritis randomised to Theracurmin 180 mg/day curcumin or placebo for 8 weeks. Knee pain VAS was lower on Theracurmin except in those with baseline VAS of 0.15 or less. Celecoxib use was lower. No major side effects reported.
Journal of Orthopaedic Science, 2014· 50 people
A very small rheumatoid arthritis pilot put 45 people on curcumin, a pain drug (diclofenac), or both. Disease scores improved in all three groups, and the curcumin-only group improved most. 45 people split three ways cannot settle a long-term disease. Treat it as a reason to run a proper study, not as proof.
The numbers 45 adults with active rheumatoid arthritis randomised to curcumin 500 mg, diclofenac 50 mg, or both. DAS28 and ACR scores improved in all three arms, with the largest percentage improvement on curcumin alone. Pilot size.
Phytotherapy Research, 2012· 45 people
Other compounds
3 compounds · 494 people given one of themApproved drugs, biologics and hormones that have been measured for this. They are here because leaving them out would misrepresent the evidence, and they are below the peptides because that is not what most people come here to read.
- 01MethotrexateSmall moleculeStrong. At least two finished studies in people, and at least 1,000 people who took it. 2 completed trials, 5,022 people given it.4 reported236 people given it1 trial
A year of methotrexate given before rheumatoid arthritis was diagnosed did not stop the arthritis from arriving. 236 adults with joint pain took part. They also got one steroid shot at the start. They did have less pain, stiffness and joint inflammation two years on. One region, and an early test of the idea.
The numbers 236 adults with arthralgia and MRI-detected subclinical joint inflammation randomised double-blind to a single 120 mg intramuscular glucocorticoid injection plus 1 year of oral methotrexate up to 25 mg weekly, or placebo, followed for 2 years. Persistent clinical arthritis in 19% versus 18% (HR 0.81, 95% CI 0.45 to 1.48). Physical functioning (HAQ difference -0.09), pain (-8 on a 0 to 100 scale), morning stiffness (-12) and MRI-detected inflammation (-1.4 points) better on methotrexate; serious adverse events equal.
The Lancet, 2022· 236 people
- 02UBX0101Small moleculeModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 183 people given it.3 reported183 people given it1 trial
The first clean-up drug ever tested against a real symptom in people failed. 183 people with knee arthritis got one shot of UBX0101 at one of three strengths, or a dummy shot. After 12 weeks, knee pain had fallen from about 2.1 to 1.12 on the dummy shot and to between 1.04 and 1.16 on the drug. Knee function and daily pain matched too. One person in the highest dose group died, with no cause given in the record.
The numbers Unity Biotechnology, phase 2, randomised, triple masked, 183 participants (placebo 46, UBX0101 0.5 mg 45, 2.0 mg 46, 4.0 mg 46). Results posted December 2021. WOMAC pain subscale fell from about 2.1 at baseline to 1.12 on placebo versus 1.16, 1.04 and 1.10 on the three doses at week 12. Function and daily pain scores likewise showed no separation. Serious adverse events 1, 2, 1 and 3 by arm; one death recorded in the 4.0 mg arm, cause not given in the posting.
ClinicalTrials.gov, 2026· 183 people
Also measured in animals or in the lab
In mice. In mice bred so worn-out cells could be tracked and killed, clearing worn-out cells after a knee ligament injury eased arthritis and pain and helped cartilage grow. A clean-up drug injected into the knee did the same in normal and old mice. Cells from people having knee replacements were treated in a dish, not in the people.
The numbers Mouse. Using the p16-3MR transgenic model after anterior cruciate ligament transection, selective elimination of senescent cells attenuated post-traumatic osteoarthritis, reduced pain and increased cartilage development, reproduced by intra-articular injection of a senolytic molecule in transgenic, non-transgenic and aged mice. Cells from patients undergoing knee replacement were treated in culture, not in the patients.
Nature Medicine, 2017· animal study
- 03Alpha-2-MacroglobulinBiologicLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 75 people given it.6 reported75 people given it1 trial1 found nothing
found nothingA2M injections helped knees, but no better than the cheaper options they were tested against. 75 people with moderate knee osteoarthritis were split by chance between an A2M-rich concentrate, ordinary platelet-rich plasma, and a steroid injection. Nobody involved knew which. 68 finished. At 12 weeks the A2M group had improved on every pain and function score, the platelet group on none, and the steroid group on one. But the groups did not differ from each other. The authors concluded A2M is not worth its higher cost.
The numbers Double-blinded randomised controlled trial at a single centre, enrolling June 2018 to May 2019. 75 people with symptomatic Kellgren-Lawrence grade 2 or 3 knee osteoarthritis randomised to intra-articular A2M-rich concentrate, conventional platelet-rich plasma, or methylprednisolone, followed 12 weeks; 68 (90.7 percent) completed, 73 percent female, mean age 59. At 12 weeks the A2M group improved significantly on visual analogue scale, WOMAC, KOOS and Tegner; the platelet-rich plasma group improved on nothing; the steroid group improved on Lysholm only. Between-group changes did not differ significantly. The authors concluded A2M is not superior and, given higher preparation cost, may not be justifiable for routine treatment.
Bulletin of the Hospital for Joint Diseases, 2024· 75 people
What people using it report
- A2M shots are sold in bone, joint and regenerative medicine clinics for knee and other joint arthritis. The protein is concentrated from a sample of the patient's own blood, in the clinic, on the day. It is sold on the idea that it blocks the enzymes that eat away at cartilage.
- The trial that tested this records what the procedure involves and who gets it: people whose knee arthritis shows on x-ray at the middle grades of severity, average age 59, mostly women, given a single shot into the joint.
Also measured in animals or in the lab
In minipigs, A2M cut cartilage damage after a joint injury by calming inflammation. The model combined an injury to the joint with a drilling technique used to prompt repair.
The numbers Minipig. A2M reduced post-traumatic osteoarthritis cartilage damage by inhibiting inflammatory pathways, in a model combining joint injury with modified intra-articular drilling.
American Journal of Sports Medicine, 2024· animal study
What people using these actually report
These are people describing their own use. They come from clinic write-ups, complaint records kept by regulators, and public forums, and they are shown as written. They are the best guide on this page to what people actually do, what they expect, and what goes wrong. They cannot show that anything works. Nobody was compared with people on a dummy pill, and people who saw no effect mostly stopped posting. Both things are true at once. The bad reports are kept in for the same reason.
- Bee venom therapy, with live stings or injected venom, has a long tradition among ordinary people for arthritis, multiple sclerosis and long term pain. The 2005 MS study was run because patients were already doing it. The Parkinson study used a standard allergy shot dosing plan for the same reason.
Sources: The published apitherapy and bee venom acupuncture literature, including the Toxicon 2018 review, the Korean safety trial of filtered versus unfiltered venom, the recruitment rationale stated in the MS and Parkinson trials, and the registered Apitox trials. No forum or social media content was retrieved for this entry and nothing here is attributed to a specific post.
- A2M shots are sold in bone, joint and regenerative medicine clinics for knee and other joint arthritis. The protein is concentrated from a sample of the patient's own blood, in the clinic, on the day. It is sold on the idea that it blocks the enzymes that eat away at cartilage.
- The trial that tested this records what the procedure involves and who gets it: people whose knee arthritis shows on x-ray at the middle grades of severity, average age 59, mostly women, given a single shot into the joint.
Sources: The published study in the Bulletin of the Hospital for Joint Diseases 2024, which is the source for the procedure description, the population treated, the comparators and the cost conclusion; the 2015 PLoS One naked mole rat comparative study, which is the source of the longevity rationale that appears in marketing. No clinic website, forum post or individual patient account is quoted or relied on here.
- Joint pain is what people say they are after, and relief is commonly described over roughly six to eight weeks, with shoulders, knees and wrists described more often than spine or neck.
- The most important recurring caution is that relief is masking rather than repair. Moderators make the point repeatedly that cartilage and tendon damage is still there, and that the predictable sequence is feeling better, training harder because strength is up, and re-injuring the same joint.
- One dissenting line runs through the joint pain threads: that training technique and load management matter more than the drug, and that without changing those the injury comes back regardless.
Sources: Nandrolone and TRT threads on ExcelMale, including a mood poll thread, found by site-restricted search and through the site's tag index, read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
- People say they use it for tendon pain, mostly elbow, shoulder and Achilles, for partly torn muscles, for knee pain and after surgery. Some use it for gut trouble such as reflux and bowel swelling.
- Some people report new or worse tendon or joint pain while taking it. These reports are much rarer than reports of relief. No published study has looked for this on purpose.
Sources: FDA's July 2026 evaluation of BPC-157, which reproduces the FAERS side-effect reports through December 4, 2025, the Human Foods Program complaint records, and the marketed dosage forms and strengths; the three published clinic reports above, which are the only documented clinical practice; the 2025 HSS Journal systematic review and the 2026 American Journal of Sports Medicine and Sports Medicine reviews, which describe how athletes and clinicians are using these peptides and note that indications, dosing, frequency and duration all remain undefined; and public injury logs and question threads on peptide and bodybuilding forums including eroids, iSARMS, Ironsport and FITMISC. Reddit's r/Peptides and r/PeptideSupport could not be retrieved for this entry, so nothing above is attributed to any specific post, and no quotation is reproduced from any of these sources.
- The most distinctive single report is joint pain changing within hours of a dose and staying changed for much of the week. Other reports cover body weight, memory and work performance, and shifts in routine bloodwork. Attribution is loose throughout, because almost everyone posting is running several other things at the same time.
Sources: Rapamycin experience and dosing threads on LongeCity, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
- Nagging tendon or joint pain easing, described the same way people describe BPC-157 alone.
Sources: Peptide and skincare forums including r/peptides, clinic write-ups and vendor testimonial pages. No trial of this blend exists, so none of this comes from trial exit interviews or an side-effect table for the product. Most people posting are using a topical copper product at the same time as the injection, which makes attribution impossible even within the report. The FDA side-effect material comes from the agency's 2026 BPC-157 evaluation cited on this page.
- What people report changing is mixed even inside a single thread: joint pain easing, weight loss and memory change on one side, and increased appetite, visceral fat gain and disrupted sleep on the other, from people describing similar schedules.
Sources: The rapamycin personal experience thread on LongeCity read directly, plus rapamycin dosing, rapamycin vendor and acarbose versus metformin threads on the same board surfaced by site-restricted search, September 2026. No thread describing the two compounds used together was found. Nothing above is attributed to any specific post and no post is reproduced.
- A recurring corrective runs against aromatase inhibitors. People who pushed their estrogen down hard describe joint pain and flat mood, and describe regretting it. The usual first response offered to an estrogen complaint is to change dose or frequency rather than to add a drug.
Sources: Testosterone replacement threads on ExcelMale covering injection frequency, cypionate dose protocols and side effect management, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
- Less tendon and joint pain in the first few weeks, described the same way people describe BPC-157 alone.
Sources: Peptide forums including r/peptides, vendor product pages and price-comparison listings. Uncontrolled self-reports from people usually running other compounds at the same time. Recorded as reports, not evidence.
- Tendon and joint pain getting better over two to six weeks.
Sources: Peptide forums including r/peptides, clinic write-ups and vendor pages. Uncontrolled self-reports. The sting comparison in particular is unblinded and the two products look different in the vial.
- Joint pain getting better, which is what BPC-157 users report on its own.
Sources: Forums including r/peptides and r/Semaglutide, and clinic write-ups. Uncontrolled self-reports with a large confound: GLP-1 nausea reliably fades over the first weeks whether or not anything is added.
Measured in animals or in the lab, not yet in people
These are kept apart from the studies in people, not ranked against them. They answer a different question. A result in a rat is a real result, and a reason somebody ran the study. It is not a measure of what happens in you. When the work in people is missing, the reason is usually money, not failure. The bottom of this page explains why.
Peptides and blends
- 01CartalaxPeptideAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 4 lab studies, no human study.8 reported1 animal or lab study
Measured in animals or in the lab
In a dish. Aging cartilage cells gave off more aging and inflammation signals. Both Cartalax and a cartilage extract pushed those signals back toward normal. These were cells, not joints, and nobody measured a real health result.
The numbers Cell culture. The senescence-associated secretory phenotype of chondrocytes was characterised by raised p16, p21 and p53, raised TNF-alpha and IL-1-alpha, and lowered Sirt1. Both the AED peptide and a cartilage polypeptide complex normalised the synthesis of those molecules. Chondrocytes in culture, not joints, and no clinical endpoint was measured.
Advances in Gerontology, 2023· lab (cells in a dish)
Other compounds
- 01PiperlongumineSmall moleculeAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 1 animal study, 3 lab studies, no human study.2 reported1 animal or lab study
Measured in animals or in the lab
In rats. Piperlongumine cut signs of worn-out cells in knee tissue and slowed knee arthritis. The researchers also tested cells taken from people with arthritis, but only in a dish. No patients were treated.
The numbers Rat osteoarthritis model, with supporting experiments in meniscus cells and chondrocytes from patients with osteoarthritis. Piperlongumine reduced p16 and p21 and senescence-associated secretory factors and slowed disease progression in the rats. The human component is cells in a dish, not treated patients.
Biochemical and Biophysical Research Communications, 2026· animal study
Why the trial record looks like this
A missing trial usually means nobody would pay for it. Nobody spends hundreds of millions of dollars on a molecule they cannot own. So the compounds with the thinnest record in people are often the oldest and easiest to get, not the weakest. Taking Piperlongumine as the example, because it states the problem most clearly:
Piperlongumine comes from a plant. That means nobody can own it, so no company has a business reason to pay for the studies that would show what it does in people. That is a fact about money, not a verdict on the science. It cuts both ways. Without studies, nobody would spot harm or uselessness either. And the reactive chemistry that kills worn-out cells is the kind of chemistry that usually needs safety data in people before anyone takes it.
The research on it as a clean-up drug is small, recent, and mostly from the lab that found it. The arthritis result is one rat study from 2026, and nobody has repeated it.
A compound shows up here only when a study on its own page names this goal and reports a result for it. Just naming it is not enough. Work in people, in animals and in the lab is counted separately and never mixed. People counts come from the study lines, and when in doubt they count low. Nothing here is advice. Nothing here tells you to take or to avoid anything.